EMJ GOLD - European Medical Journal

Continue

Pharma News, Views & Analysis

Filter Advertise With Us
Handshake on a green background

Jazz Pharmaceuticals to acquire Chimerix in $935m deal

In a deal worth approximately $935m, Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing oncology therapies.
The word spotlight on a blue background

Spotlight: February 2025

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to the fore.

UK's NHS must boost medicine spending, ABPI warns

The UK must increase investment in innovative medicines and vaccines if it is to deliver on the NHS 10-Year Plan and drive economic growth.
White House

Trump administration cuts more than 90% of USAID funding

The Trump administration is set to cut a total of $60bn in US assistance worldwide, signalling a major shift in health policy.

Eli Lilly plans record $50bn US manufacturing investment

The company’s investment will expand its US manufacturing footprint and is the largest investment of its kind in history.
The world

EMA grants accelerated review to Gilead’s PrEP drug

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV prevention.
Handshake on a green background

AstraZeneca pays $160m for FibroGen's China subsidary

FibroGen, Inc. has announced the sale of its Chinese subsidiary to AstraZeneca, including the rights to roxadustat in China.

FDA fast-tracks Boehringer's NSCLC drug review

The FDA has granted priority review to zongertinib for non-small cell lung cancer (NSCLC).
We’ve noticed you’re accessing
from North/South America.